Table 2:
Presenting symptoms and biological evolution of SARS-CoV-2 infection
| Variables | CLD without cirrhosis (n = 22) | CLD with cirrhosis (n = 16) | LT recipients (n = 4) |
|---|---|---|---|
| COVID-19 symptoms, no. (%) | |||
| Respiratory | 12 (55) | 7 (44) | 4 (100) |
| Gastrointestinal | 1 (5) | 1 (6) | 0 (0) |
| Both | 3 (14) | 1 (6) | 0 (0) |
| No symptoms | 6 (27) | 7 (44) | 0 (0) |
| Biochemical characteristics, mean (IQR) | |||
| Serum sodium baseline, mmol/L | 140 (135–143) | 139 (135–144) | 140 (135–142) |
| Serum sodium during COVID-19, mmol/L | 137 (130–142) | 137 (117–142) | 144 (144) |
| Serum creatinine baseline, µmol/L | 80 (52–618) | 74 (54–158) | 77 (54–143) |
| Serum creatinine during COVID-19, µmol/L | 87 (46–740) | 114 (61–179) | 91 (91*) |
| Prothrombin time baseline | 12 (10–25) | 12 (11–23) | 11 (10–12) |
| Prothrombin time during COVID-19 | 12 (10–25) | 13 (11–24) | ND |
| INR baseline | 1.0 (0.9–1.3) | 1.0 (0.8–1.5) | 1.0 (0.8–1.0) |
| INR during COVID-19 | 1.0 (0.9–1.4) | 1.0 (0.9–5.5) | 0.9 (0.9*) |
| Serum albumin baseline, g/dL | 42 (25–46) | 39 (29–51) | 38 (27–48) |
| Serum albumin during COVID-19, g/dL | 36 (17–44) | 33 (22–47) | 31 (31*) |
| Total bilirubin baseline, µmol/L | 10 (4–382) | 11 (6–79) | 14 (8–21) |
| Total bilirubin during COVID-19, µmol/L | 10 (5–420) | 13 (7–189) | 6 (6*) |
| Alanine transaminase baseline, U/L | 27 (5–287) | 22 (9–106) | 19 (13–52) |
| Alanine transaminase during COVID-19, U/L | 47 (6–482) | 41 (9–116) | 23 (23*) |
| Alkaline phosphatase baseline, U/L | 69 (30–212) | 72 (48–258) | 76 (62–123) |
| Alkaline phosphatase during COVID-19, U/L | 86 (50–630) | 133 (40–500) | 100 (100*) |
* Data available for only one patient
SARS-CoV-2 = Severe acute respiratory syndrome coronavirus 2; CLD = Chronic liver disease; LT = Liver transplant; COVID-19 = Coronavirus disease 2019; ND = No data; INR = International normalized ratio